<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03037424</url>
  </required_header>
  <id_info>
    <org_study_id>16-5636-A</org_study_id>
    <nct_id>NCT03037424</nct_id>
  </id_info>
  <brief_title>FIBrinogen REplenishment in Surgery</brief_title>
  <acronym>FIBRES</acronym>
  <official_title>Prospective, Multi-center, Randomized, Active-control, Non-inferiority Study Comparing Fibrinogen Concentrate With Cryoprecipitate for the Treatment of Acquired Hypofibrinogenemia in Bleeding Adult Cardiac Surgical Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pragmatic, prospective, multi-center, randomized, active-control, single-blinded,
      non-inferiority phase 3 trial in adult cardiac surgical patients. Up to 12 Canadian hospitals
      will participate, and the trial will require up to 2 years for patient recruitment.

      Twelve-hundred bleeding adult cardiac surgical patients who require fibrinogen
      supplementation due to acquired hypofibrinogenemia after CPB will be included. Patients will
      be randomized to receive equivalent doses of either fibrinogen concentrate (Octafibrin) or
      cryoprecipitate when the blood bank receives the first order for fibrinogen supplementation
      and deems it to be in accordance with accepted clinical standards. Thereafter, patients will
      be treated according to their assigned group each time fibrinogen supplementation is ordered
      during the treatment period (24 hours after termination of CPB). No other aspects of care
      will be modified.

      The primary efficacy outcome will be the number of Allogeneic blood products (ABP) (red blood
      cells [RBCs], pooled or apheresis platelets, and plasma) administered during the first 24
      hours after termination of CPB. Safety outcomes will be measured for the first 28 days after
      surgery, which is the duration of participation of each patient in the trial. Comparisons
      will be by intention-to-treat (ITT) (primary) and per-protocol (PP) analysis. One interim
      analysis will be conducted after 600 patients have been treated to determine whether the
      study should be terminated for safety reasons, demonstrated non-inferiority or futility
      reasons.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 22, 2017</start_date>
  <completion_date type="Anticipated">March 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint, which is of efficacy, is the comparison of the total number of units of ABPs (RBCs, pooled or apheresis platelets, and plasma) administered during the first 24 hours after termination of CPB.</measure>
    <time_frame>24 hours</time_frame>
    <description>The number of ABPs (red blood cells [RBCs], pooled or apheresis platelets, and plasma) administered during the first 24 hours after termination of CPB</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Deficiency; Fibrinogen, Acquired</condition>
  <arm_group>
    <arm_group_label>Fibrinogen concentrate Octafibrin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cryoprecipitate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Octafibrin</intervention_name>
    <description>Octafibrin will be administered when the blood bank receives an order for fibrinogen supplementation</description>
    <arm_group_label>Fibrinogen concentrate Octafibrin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cryoprecipitate</intervention_name>
    <description>Cryoprecipitate will be administered when the blood bank receives an order for fibrinogen supplementation</description>
    <arm_group_label>Cryoprecipitate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. Patients undergoing cardiac surgery with CPB in whom fibrinogen supplementation is
        ordered in accordance with accepted clinical standards (significant hemorrhage and known or
        presumed hypofibrinogenemia).

        Exclusion Criteria:

          1. Receipt of fibrinogen-containing products, including concentrate or cryoprecipitate
             within 24 hours before surgery (to exclude patients with significant blood loss before
             surgery)

          2. History of severe allergic reaction to cryoprecipitate or fibrinogen concentrate

          3. Refusal of fibrinogen concentrate or cryoprecipitate due to religious or other reasons

          4. Fibrinogen level known to be &gt;3.0 g/L within 30 minutes of IMP order (to eliminate the
             risk of raising patients' fibrinogen levels to &gt;4.0 g/L with supplementation, which is
             the upper limit of the normal range)

          5. Known pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keyvan Karkouti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Keyvan Karkouti, MD</last_name>
    <phone>416-340-4800</phone>
    <phone_ext>8597</phone_ext>
    <email>keyvan.karkouti@uhn.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jo Carroll</last_name>
    <phone>416-340-4800</phone>
    <phone_ext>3243</phone_ext>
    <email>jo.carroll@uhn.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alberta/Mazankowski Heart Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Susan Nahirniak, MD</last_name>
      <phone>780-407-3426</phone>
      <email>Susan.Nahirniak@albertahealthservices.ca</email>
    </contact>
    <investigator>
      <last_name>Blaine Achen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fraser University Royal Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V3L 3W7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sukh Brar, MD</last_name>
      <phone>604-520-4273</phone>
      <email>sukhpalbrar@me.com</email>
    </contact>
    <investigator>
      <last_name>Daniel Wong</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Manitoba, St Boniface General Hospital</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R2H 2A6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ping Sun, MD</last_name>
      <phone>204-258-1114</phone>
      <email>psun@dsmanitoba.ca</email>
    </contact>
    <investigator>
      <last_name>Hilary Grocott, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Science Centre, McMaster University</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8S 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Summer Syed, MD</last_name>
      <phone>905-521-2100</phone>
      <phone_ext>76404</phone_ext>
      <email>syeds@mcmaster.ca</email>
    </contact>
    <investigator>
      <last_name>Michelle Zeller, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kingston General Hsopital</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 3N6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lois Shepherd, MD</last_name>
      <phone>613-548-7850</phone>
      <email>lshepherd@ctg.queensu.ca</email>
    </contact>
    <investigator>
      <last_name>Joel Parlow, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrew Hamilton, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Health Science Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ian Chin-Yee, MD</last_name>
      <phone>519-685-8500</phone>
      <email>Ian.Chinyee@lhsc.on.ca</email>
    </contact>
    <investigator>
      <last_name>Chris Harle, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mackenzie Quartz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Trillium Health Partners</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5B 1B8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bill Wong, MD</last_name>
      <phone>905-848-7100</phone>
      <email>bill.wong@thp.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4W7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Diem Tran, MD</last_name>
      <phone>613-761-4897</phone>
      <email>DTran@ottawaheart.ca</email>
    </contact>
    <investigator>
      <last_name>Alan Tinmouth, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Science Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jeannie Callum, MD</last_name>
      <phone>(416) 480-4757</phone>
      <email>Jeannie.Callum@sunnybrook.ca</email>
    </contact>
    <investigator>
      <last_name>Sophia Wong, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fuad Moussa, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Katerina Pavenski, MD</last_name>
      <phone>416-864-5058</phone>
      <email>PavenskiK@smh.ca</email>
    </contact>
    <investigator>
      <last_name>David Mazer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark Peterson, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tornoto General Hospital, University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keyvan Karkouti, MD</last_name>
      <phone>416-340-4800</phone>
      <phone_ext>8597</phone_ext>
      <email>keyvan.karkouti@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Warren Luksun, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vivek Rao, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stuart McCluskey, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Orlov, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire de Cardiologie et de Pneumologie de Québec- Université Laval</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean Bussières, MD</last_name>
      <phone>418 656-4870</phone>
      <email>jbuss@criucpq.ulaval.ca</email>
    </contact>
    <investigator>
      <last_name>Vincent Laroche, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre Voisine, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2017</study_first_submitted>
  <study_first_submitted_qc>January 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2017</study_first_posted>
  <last_update_submitted>April 4, 2018</last_update_submitted>
  <last_update_submitted_qc>April 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Health Network, Toronto</investigator_affiliation>
    <investigator_full_name>Jo Carroll</investigator_full_name>
    <investigator_title>Manager Anesthesia Research</investigator_title>
  </responsible_party>
  <keyword>Cyroprecipitate</keyword>
  <keyword>Fibrinogen</keyword>
  <keyword>Cardiac Surgery</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

